{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-055100","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.878711+00:00","generated_at":"2026-05-20T02:51:44.296999+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Theravance Biopharma sells remaining Trelegy royalty interest to GSK for $225M","bullets":["Sells outer-year Trelegy royalties to GSK for $225M cash; transaction closed May 30, 2025.","Retains right to up to $150M in milestones from Royalty Pharma on 2025/2026 net sales.","First outcome from Strategic Review Committee formed Nov 2024; board committed to returning excess capital.","Total potential lifetime value from Trelegy monetization now $1.525B including prior $1.1B upfront.","2025 financial guidance unchanged; company continues to focus on YUPELRI and ampreloxetine."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-055100","json":"https://secwatch.observer/filing/0001104659-25-055100.json","markdown":"https://secwatch.observer/filing/0001104659-25-055100.md","text":"https://secwatch.observer/filing/0001104659-25-055100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925055100/0001104659-25-055100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925055100/tm2516518d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:51:44.296999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7e14eb759d4625a88d5ed4acfb24e7c051177081","claim":"Theravance Biopharma, Inc. completed a disposition involving GlaxoSmithKline Intellectual Property Development Limited for $225 million (closed 2025-05-30).","evidence_excerpt":"ompany (“TBPH”) and GlaxoSmithKline Intellectual Property Development Limited, a private company limited by shares registered","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925055100/0001104659-25-055100-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"GlaxoSmithKline Intellectual Property Development Limited"},{"label":"Consideration","value":"$225 million"},{"label":"Closing","value":"2025-05-30"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}